AR122350A1 - PHARMACEUTICAL COMPOSITIONS - Google Patents
PHARMACEUTICAL COMPOSITIONSInfo
- Publication number
- AR122350A1 AR122350A1 ARP200103416A ARP200103416A AR122350A1 AR 122350 A1 AR122350 A1 AR 122350A1 AR P200103416 A ARP200103416 A AR P200103416A AR P200103416 A ARP200103416 A AR P200103416A AR 122350 A1 AR122350 A1 AR 122350A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- hiv
- treatment against
- cabotegravir
- poloxamer
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- WCWSTNLSLKSJPK-LKFCYVNXSA-N cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 abstract 1
- 229950005928 cabotegravir Drugs 0.000 abstract 1
- 238000011866 long-term treatment Methods 0.000 abstract 1
- 229960000502 poloxamer Drugs 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere al tratamiento contra el Virus de Inmunodeficiencia Humana (HIV). En particular, la invención se refiere a una composición farmacéutica que comprende cabotegravir o una sal apta para uso farmacéutico del mismo, polietilenglicol y poloxámero que es útil para el tratamiento de larga duración contra el HIV.The present invention refers to the treatment against the Human Immunodeficiency Virus (HIV). In particular, the invention relates to a pharmaceutical composition comprising cabotegravir or a pharmaceutically acceptable salt thereof, polyethylene glycol and poloxamer which is useful for long-term treatment against HIV.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945412P | 2019-12-09 | 2019-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122350A1 true AR122350A1 (en) | 2022-09-07 |
Family
ID=83444530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103416A AR122350A1 (en) | 2019-12-09 | 2020-12-09 | PHARMACEUTICAL COMPOSITIONS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR122350A1 (en) |
-
2020
- 2020-12-09 AR ARP200103416A patent/AR122350A1/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38982A (en) | PHARMACEUTICAL COMPOSITIONS | |
| CU20150096A7 (en) | AMIDA COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR HIV TREATMENT | |
| CL2017001191A1 (en) | Compounds derived from polycyclic carbamoylpyridone; pharmaceutical composition comprising them; and its use for the treatment of a hiv infection in a human who has or is at risk of having the infection. | |
| BR112015013695A2 (en) | pharmaceutical composition and methods for treating and preventing an HIV infection | |
| CL2017000379A1 (en) | Pyrrolopyrimidine compounds used as toll receptor agonists. 7 (tlr7) | |
| UY37998A (en) | ANTIVIRAL AGENTS AGAINST HEPATITIS B | |
| DOP2017000137A (en) | BENZAMIDES SUBSTITUTED WITH 1,3-THIAZOL-2-ILO. | |
| TR201909152T4 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use. | |
| NI201700101A (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING N - (3, 5 - DIMETOXIPHENIL) - N'- (1-METHYLETHYL) - N - [3- (1-METHYL-1H-PIRAZOL-4-IL) QUINOXALINE-6-IL] ETHANE-1 , 2-DIAMINE | |
| CL2018000222A1 (en) | New combination for use in cancer treatment | |
| UY37741A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRUS REPLICATION | |
| CO2020002980A2 (en) | Antiviral agents against hepatitis b. | |
| CL2018001199A1 (en) | Therapeutic compositions for the treatment of human immunodeficiency virus | |
| CL2020002252A1 (en) | Ophthalmic formulation. | |
| CL2017001483A1 (en) | Fixed ratio formulation of insulin glargine / lixisenatide | |
| MX393782B (en) | LONG-TERM FORMULATIONS | |
| CL2019003572A1 (en) | Low-dose brimonidine combinations and uses thereof. | |
| MX2020012058A (en) | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER. | |
| MX390536B (en) | TOPICAL PHARMACEUTICAL COMPOSITION INCLUDING AT LEAST AMITRIPTYLINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN. | |
| CL2021001636A1 (en) | Pharmaceutical composition for the treatment of pulmonary arterial hypertension | |
| AR120655A1 (en) | BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV | |
| CL2017000714A1 (en) | Long-acting pharmaceutical compositions | |
| UY38067A (en) | MODIFIED RELAXIN B-CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | |
| AR122350A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| CL2021000858A1 (en) | Derivatives of 4-pyrazin-2-ylmethyl-morpholine and their use as a medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |